• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

扩大淋巴结清扫术与有限淋巴结清扫术对pN0期近端进展期胃癌的预后影响:一项倾向评分匹配分析

Prognostic Impact of Extended Lymph Node Dissection versus Limited Lymph Node Dissection on pN0 Proximal Advanced Gastric Cancer: a Propensity Score Matching Analysis.

作者信息

Park Sung Hyun, Son Taeil, Seo Won Jun, Lee Joong Ho, Choi Youn Young, Kim Hyoung-Il, Cheong Jae-Ho, Noh Sung Hoon, Hyung Woo Jin

机构信息

Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

Gastric Cancer Center, Yonsei Cancer Center, Seoul, Korea.

出版信息

J Gastric Cancer. 2019 Jun;19(2):212-224. doi: 10.5230/jgc.2019.19.e20. Epub 2019 Jun 7.

DOI:10.5230/jgc.2019.19.e20
PMID:31245166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6589420/
Abstract

PURPOSE

Splenic hilar lymph node dissection (LND) during total gastrectomy is regarded as the standard treatment for proximal advanced gastric cancer (AGC). This study aimed to investigate whether splenic hilar LND or D2 LND is essential for proximal AGC of pT2-4aN0M0 stage.

MATERIALS AND METHODS

Data of curative total gastrectomies (n=370) performed from 2000 to 2010 for proximal AGC of pT2-4aN0 stage were retrospectively reviewed. Clinicopathological characteristics and long-term outcomes were compared using propensity score matching between patients who underwent splenectomy (n=43) and those who did not (n=327) and between patients who underwent D2 LND (n=122) and those who underwent D1+ LND (n=248).

RESULTS

Tumors of larger size and a more advanced T stage and significantly lower overall and relapse-free survival (P<0.001) were observed in the splenectomy group than in the 2 spleen-preserving groups. Before propensity score matching, worse overall and relapse-free survival (P<0.001) was observed in the splenectomy group than in the non-splenectomy group. After matching, although the overall survival became similar (P=0.123), relapse-free survival was worse in the splenectomy group (P=0.021). Compared with D1+ LND, D2 LND had no positive impact on the overall (P=0.619) and relapse-free survival (P=0.112) after propensity score matching.

CONCLUSIONS

Splenic hilar LND with or without splenectomy may not have an oncological benefit for patients with pathological AGC with no LN metastasis.

摘要

目的

全胃切除术中脾门淋巴结清扫术(LND)被视为近端进展期胃癌(AGC)的标准治疗方法。本研究旨在探讨脾门LND或D2 LND对于pT2 - 4aN0M0期近端AGC是否必不可少。

材料与方法

回顾性分析2000年至2010年因pT2 - 4aN0期近端AGC行根治性全胃切除术(n = 370)的数据。采用倾向评分匹配法比较行脾切除术的患者(n = 43)和未行脾切除术的患者(n = 327)之间,以及行D2 LND的患者(n = 122)和行D1 + LND的患者(n = 248)之间的临床病理特征和长期预后。

结果

与两个保脾组相比,脾切除术组观察到肿瘤体积更大、T分期更晚,总体生存率和无复发生存率显著更低(P < 0.001)。在倾向评分匹配前,脾切除术组的总体生存率和无复发生存率比非脾切除术组更差(P < 0.001)。匹配后,尽管总体生存率变得相似(P = 0.123),但脾切除术组的无复发生存率更差(P = 0.021)。倾向评分匹配后,与D1 + LND相比,D2 LND对总体生存率(P = 0.619)和无复发生存率(P = 0.112)没有积极影响。

结论

对于无淋巴结转移的病理AGC患者,无论是否行脾切除术,脾门LND可能都没有肿瘤学益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/e5da4947cd91/jgc-19-212-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/9028e9a8d2f7/jgc-19-212-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/c631781ee884/jgc-19-212-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/226c9bce8695/jgc-19-212-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/e5da4947cd91/jgc-19-212-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/9028e9a8d2f7/jgc-19-212-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/c631781ee884/jgc-19-212-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/226c9bce8695/jgc-19-212-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67d1/6589420/e5da4947cd91/jgc-19-212-g004.jpg

相似文献

1
Prognostic Impact of Extended Lymph Node Dissection versus Limited Lymph Node Dissection on pN0 Proximal Advanced Gastric Cancer: a Propensity Score Matching Analysis.扩大淋巴结清扫术与有限淋巴结清扫术对pN0期近端进展期胃癌的预后影响:一项倾向评分匹配分析
J Gastric Cancer. 2019 Jun;19(2):212-224. doi: 10.5230/jgc.2019.19.e20. Epub 2019 Jun 7.
2
Comparison of long term survival outcomes between D1+ and D2 lymph node dissection for ≥ pT2 or pN+ gastric carcinoma: A large scale case-control study using propensity score matching.比较 D1+ 和 D2 淋巴结清扫术对≥pT2 或 pN+ 胃癌患者长期生存结局的影响:一项使用倾向评分匹配的大型病例对照研究。
Eur J Surg Oncol. 2020 Jul;46(7):1239-1246. doi: 10.1016/j.ejso.2020.04.013. Epub 2020 Apr 14.
3
Is Splenic Hilar Lymph Node Dissection Without Splenectomy Essential for Proximal Advanced Gastric Cancer?脾门淋巴结清扫术在近端进展期胃癌中是否必要?
Ann Surg Oncol. 2021 Dec;28(13):8952-8961. doi: 10.1245/s10434-021-10354-x. Epub 2021 Jul 17.
4
The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China.保留脾脏的淋巴结清扫术在全胃切除治疗胃及胃食管结合部腺癌中的价值:来自中国一家大容量医疗机构的长期回顾性倾向评分匹配研究。
Surgery. 2021 Feb;169(2):426-435. doi: 10.1016/j.surg.2020.07.053. Epub 2020 Sep 17.
5
The effects of laparoscopic spleen-preserving splenic hilar lymphadenectomy on the surgical outcome of proximal gastric cancer: a propensity score-matched, case-control study.腹腔镜保留脾脏的脾门淋巴结清扫术对近端胃癌手术结局的影响:一项倾向评分匹配的病例对照研究。
Surg Endosc. 2017 Mar;31(3):1383-1392. doi: 10.1007/s00464-016-5126-0. Epub 2016 Jul 22.
6
Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study.胃近端癌脾门淋巴结清扫的临床意义:倾向评分匹配病例对照研究。
Ann Surg Oncol. 2021 Oct;28(11):6649-6662. doi: 10.1245/s10434-021-09830-1. Epub 2021 Mar 25.
7
Risk evaluation of splenic hilar or splenic artery lymph node metastasis and survival analysis for patients with proximal gastric cancer after curative gastrectomy: a retrospective study.根治性胃切除术后近端胃癌患者脾门或脾动脉淋巴结转移的风险评估和生存分析:一项回顾性研究。
BMC Cancer. 2019 Sep 11;19(1):905. doi: 10.1186/s12885-019-6112-4.
8
Can laparoscopic spleen-preserving splenic hilar lymph node dissection replace prophylactic splenectomy for proximal advanced gastric cancers that invade the greater curvature?腹腔镜保留脾脏脾门淋巴结清扫术能否替代预防性脾切除术治疗侵犯大弯侧的近端进展期胃癌?
Eur J Surg Oncol. 2021 Jun;47(6):1466-1472. doi: 10.1016/j.ejso.2020.11.133. Epub 2020 Nov 26.
9
Advantages of Splenic Hilar Lymph Node Dissection in Proximal Gastric Cancer Surgery.脾门淋巴结清扫在近端胃癌手术中的优势
J Gastric Cancer. 2020 Mar;20(1):19-28. doi: 10.5230/jgc.2020.20.e10. Epub 2020 Mar 20.
10
Analysis of the short- and long-term outcomes of membrane anatomy-guided laparoscopic spleen-preserving circumferential splenic hilar lymph node dissection for treating advanced proximal gastric cancer.分析膜解剖引导下腹腔镜保留脾脏的胃周脾门淋巴结清扫术治疗进展期近端胃癌的近期和远期疗效。
World J Surg Oncol. 2019 Apr 9;17(1):64. doi: 10.1186/s12957-019-1610-z.

引用本文的文献

1
Lymph Node Dissection of Choice in Older Adult Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.老年胃癌患者的选择性淋巴结清扫:一项系统评价与Meta分析
J Clin Med. 2024 Dec 17;13(24):7678. doi: 10.3390/jcm13247678.
2
Efficacy of the No. 10 lymphadenectomy with spleen preservation on patients with gastric cancer and/or esophagogastric junction adenocarcinoma who underwent total gastrectomy: a systematic review and meta-analysis.保留脾脏的第10组淋巴结清扫术对接受全胃切除术的胃癌和/或食管胃交界腺癌患者的疗效:一项系统评价和荟萃分析。
Transl Cancer Res. 2022 Sep;11(9):3024-3038. doi: 10.21037/tcr-22-522.
3

本文引用的文献

1
Impact of splenic hilar lymph node metastasis on prognosis in patients with advanced gastric cancer.脾门淋巴结转移对进展期胃癌患者预后的影响
Oncotarget. 2017 Jun 28;8(48):84515-84528. doi: 10.18632/oncotarget.18762. eCollection 2017 Oct 13.
2
Prognostic factors for survival in patients with pT1 N+ or T2-3 N0 gastric cancer in Japan.日本 pT1N+或 T2-3N0 胃癌患者生存的预后因素。
Br J Surg. 2017 Jun;104(7):885-890. doi: 10.1002/bjs.10509. Epub 2017 Feb 27.
3
Splenic hilar dissection in the treatment of proximal advanced gastric cancer: what is an adequate strategy?
Elevated carbohydrate antigen 125 post-operation as a prognostic marker in gastric cancer patients with stage II-III.
术后糖类抗原125升高作为Ⅱ-Ⅲ期胃癌患者的预后标志物
Transl Cancer Res. 2020 Sep;9(9):5200-5208. doi: 10.21037/tcr-19-2427.
4
The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.胃神经内分泌癌的临床病理特征和总生存分析。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211055340. doi: 10.1177/15330338211055340.
5
Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients.用于评估胃癌患者术后及辅助化疗获益风险的整合放射基因组学方法
Front Oncol. 2021 Nov 5;11:755271. doi: 10.3389/fonc.2021.755271. eCollection 2021.
脾门淋巴结清扫术治疗进展期近端胃癌:何种策略才恰当?
Transl Gastroenterol Hepatol. 2016 Sep 21;1:72. doi: 10.21037/tgh.2016.09.05. eCollection 2016.
4
Comparison of different methods of splenic hilar lymph node dissection for advanced upper- and/or middle-third gastric cancer.进展期胃上和/或胃中上部癌不同脾门淋巴结清扫方法的比较
BMC Cancer. 2016 Oct 3;16(1):765. doi: 10.1186/s12885-016-2814-z.
5
Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma.评估近端胃癌全胃切除术中脾切除术的随机对照试验
Ann Surg. 2017 Feb;265(2):277-283. doi: 10.1097/SLA.0000000000001814.
6
Clinical Significance of Splenic Hilar Dissection with Splenectomy in Advanced Proximal Gastric Cancer: An Analysis at a Single Institution in Japan.进展期近端胃癌脾门淋巴结清扫联合脾切除术的临床意义:日本单机构分析
World J Surg. 2016 May;40(5):1165-71. doi: 10.1007/s00268-015-3362-4.
7
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
8
Japanese classification of gastric carcinoma: 3rd English edition.日本胃癌分类:第3版英文版
Gastric Cancer. 2011 Jun;14(2):101-12. doi: 10.1007/s10120-011-0041-5.
9
Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients.脾门淋巴结清扫术联合脾切除术对胃癌患者生存获益的影响:亚组患者获益的相对比较。
Gastric Cancer. 2011 Jun;14(2):172-7. doi: 10.1007/s10120-011-0028-2. Epub 2011 Feb 18.
10
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.胃癌的外科治疗:随机全国性荷兰 D1D2 试验的 15 年随访结果。
Lancet Oncol. 2010 May;11(5):439-49. doi: 10.1016/S1470-2045(10)70070-X. Epub 2010 Apr 19.